Needham initiated coverage of Revance Therapeutics (NASDAQ:RVNC) with a “buy” rating and $42 price target. The stock closed at $30.60 on March 26.Read More
Athersys (NASDAQ:ATHX) priced a public offering of 19,802,000 common shares at a price of $1.01 each for gross proceeds of about $20-million and gave underwriters an option to purchase up to an additional 2,970,300 shares.Read More
Jeff Sacher has joined Aegis Capital to lead the firm's global healthcare effort as a managing director.
Previously, Mr. Sacher was a senior banker at Goldman Sachs, Needham and Brean Capital. In addition, he has served as CFO for Viacell, a stem cell company purchased by PerkinElmer.Read More